GSK's Strategic Leap: Acquiring IDRx for $1.15 Billion to Revolutionize GIST Treatment
In a groundbreaking move, GSK is set to acquire Boston-based biotech firm IDRx for up to $1.15 billion. This acquisition aims to bolster GSK's oncology portfolio with innovative therapies for gastrointestinal stromal tumors (GIST), addressing unmet medical needs. With $1 billion paid upfront, this deal highlights GSK's commitment to advancing cancer treatment options.
Jan 17